Lundbeck at BIO-Europe 2026
Nov 9–11, 2026 Cologne, Germany ~5.8k attendees Website
Lundbeck takes part in 2 sessions at BIO-Europe 2026 in Cologne. Its sessions cover scaling biologics manufacturing in a changing world and early experience with the Health Technology Assessment (HTA) regulation. The HTA session, shared with EUCOPE, looks at what the rules mean for reimbursement.
| Organization | BIO-Europe 2026 Attendance |
|---|---|
Lundbeck Copenhagen, Denmark | |
Danish pharmaceutical company focused on brain diseases, including psychiatry, neurology and migraine. | Panel Tue Nov 10 15:00–15:25 Scaling Biologics Manufacturing in a Changing World: How Biopharma is Rethinking Launches, Partnerships and Resilience How political uncertainty and trade shifts are changing how drug companies pick outside manufacturers, including whether to produce closer to home. Panel Wed Nov 11 13:00–13:45 HTA Regulation: Early Insights and Reimbursement Implications Early lessons from the EU's new joint reviews of how much new drugs help patients, and whether they ease or hinder patient access. |
Instantly find 20 buyers from Lundbeck
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by EBD Group, Informa Connect or BIO-Europe. Submit a correction